Cargando…

Pharmacogenetic Analysis of Pediatric Patients with Acute Lymphoblastic Leukemia: A Possible Association between Survival Rate and ITPA Polymorphism

Genetic polymorphisms are important factors in the effects and toxicity of chemotherapeutics. To analyze the pharmacogenetic and ethnic differences in chemotherapeutics, major genes implicated in the treatment of acute lymphoblastic leukemia (ALL) were analyzed. Eighteen loci of 16 genes in 100 pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Hyery, Kang, Hyoung Jin, Kim, Hyo Jeong, Jang, Mi Kyung, Kim, Nam Hee, Oh, Yongtaek, Han, Byoung-Don, Choi, Ji-Yeob, Kim, Chul Woo, Lee, Ji Won, Park, Kyung Duk, Shin, Hee Young, Ahn, Hyo Seop
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3454425/
https://www.ncbi.nlm.nih.gov/pubmed/23029095
http://dx.doi.org/10.1371/journal.pone.0045558
_version_ 1782244503009099776
author Kim, Hyery
Kang, Hyoung Jin
Kim, Hyo Jeong
Jang, Mi Kyung
Kim, Nam Hee
Oh, Yongtaek
Han, Byoung-Don
Choi, Ji-Yeob
Kim, Chul Woo
Lee, Ji Won
Park, Kyung Duk
Shin, Hee Young
Ahn, Hyo Seop
author_facet Kim, Hyery
Kang, Hyoung Jin
Kim, Hyo Jeong
Jang, Mi Kyung
Kim, Nam Hee
Oh, Yongtaek
Han, Byoung-Don
Choi, Ji-Yeob
Kim, Chul Woo
Lee, Ji Won
Park, Kyung Duk
Shin, Hee Young
Ahn, Hyo Seop
author_sort Kim, Hyery
collection PubMed
description Genetic polymorphisms are important factors in the effects and toxicity of chemotherapeutics. To analyze the pharmacogenetic and ethnic differences in chemotherapeutics, major genes implicated in the treatment of acute lymphoblastic leukemia (ALL) were analyzed. Eighteen loci of 16 genes in 100 patients with ALL were analyzed. The distribution of variant alleles were CYP3A4*1B (0%), CYP3A5*3 (0%), GSTM1 (21%), GSTP1 (21%), GSTT1 (16%), MDR1 exon 21 (77%), MDR1 exon 26 (61%), MTHFR 677 (63%), MTHFR 1298 (29%), NR3C1 1088 (0%), RFC1 80 (68%), TPMT combined genotype (7%), VDR intron 8 (11%), VDR FokI (83%), TYMS enhancer repeat (22%) and ITPA 94 (30%). The frequencies of single nucleotide polymorphisms (SNPs) of 10 loci were statistically different from those in Western Caucasians. Dose percents (actual/planned dose) or toxicity of mercaptopurine and methotrexate were not related to any SNPs. Event free survival (EFS) rate was lower in ITPA variants, and ITPA 94 AC/AA variant genotypes were the only independent risk factor for lower EFS in multivariate analysis, which was a different pharmacogenetic implication from Western studies. This study is the first pharmacogenetic study in Korean pediatric ALL. Our result suggests that there are other possible pharmacogenetic factors besides TPMT or ITPA polymorphisms which influence the metabolism of mercaptopurine in Asian populations.
format Online
Article
Text
id pubmed-3454425
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-34544252012-10-01 Pharmacogenetic Analysis of Pediatric Patients with Acute Lymphoblastic Leukemia: A Possible Association between Survival Rate and ITPA Polymorphism Kim, Hyery Kang, Hyoung Jin Kim, Hyo Jeong Jang, Mi Kyung Kim, Nam Hee Oh, Yongtaek Han, Byoung-Don Choi, Ji-Yeob Kim, Chul Woo Lee, Ji Won Park, Kyung Duk Shin, Hee Young Ahn, Hyo Seop PLoS One Research Article Genetic polymorphisms are important factors in the effects and toxicity of chemotherapeutics. To analyze the pharmacogenetic and ethnic differences in chemotherapeutics, major genes implicated in the treatment of acute lymphoblastic leukemia (ALL) were analyzed. Eighteen loci of 16 genes in 100 patients with ALL were analyzed. The distribution of variant alleles were CYP3A4*1B (0%), CYP3A5*3 (0%), GSTM1 (21%), GSTP1 (21%), GSTT1 (16%), MDR1 exon 21 (77%), MDR1 exon 26 (61%), MTHFR 677 (63%), MTHFR 1298 (29%), NR3C1 1088 (0%), RFC1 80 (68%), TPMT combined genotype (7%), VDR intron 8 (11%), VDR FokI (83%), TYMS enhancer repeat (22%) and ITPA 94 (30%). The frequencies of single nucleotide polymorphisms (SNPs) of 10 loci were statistically different from those in Western Caucasians. Dose percents (actual/planned dose) or toxicity of mercaptopurine and methotrexate were not related to any SNPs. Event free survival (EFS) rate was lower in ITPA variants, and ITPA 94 AC/AA variant genotypes were the only independent risk factor for lower EFS in multivariate analysis, which was a different pharmacogenetic implication from Western studies. This study is the first pharmacogenetic study in Korean pediatric ALL. Our result suggests that there are other possible pharmacogenetic factors besides TPMT or ITPA polymorphisms which influence the metabolism of mercaptopurine in Asian populations. Public Library of Science 2012-09-24 /pmc/articles/PMC3454425/ /pubmed/23029095 http://dx.doi.org/10.1371/journal.pone.0045558 Text en © 2012 Kim et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Kim, Hyery
Kang, Hyoung Jin
Kim, Hyo Jeong
Jang, Mi Kyung
Kim, Nam Hee
Oh, Yongtaek
Han, Byoung-Don
Choi, Ji-Yeob
Kim, Chul Woo
Lee, Ji Won
Park, Kyung Duk
Shin, Hee Young
Ahn, Hyo Seop
Pharmacogenetic Analysis of Pediatric Patients with Acute Lymphoblastic Leukemia: A Possible Association between Survival Rate and ITPA Polymorphism
title Pharmacogenetic Analysis of Pediatric Patients with Acute Lymphoblastic Leukemia: A Possible Association between Survival Rate and ITPA Polymorphism
title_full Pharmacogenetic Analysis of Pediatric Patients with Acute Lymphoblastic Leukemia: A Possible Association between Survival Rate and ITPA Polymorphism
title_fullStr Pharmacogenetic Analysis of Pediatric Patients with Acute Lymphoblastic Leukemia: A Possible Association between Survival Rate and ITPA Polymorphism
title_full_unstemmed Pharmacogenetic Analysis of Pediatric Patients with Acute Lymphoblastic Leukemia: A Possible Association between Survival Rate and ITPA Polymorphism
title_short Pharmacogenetic Analysis of Pediatric Patients with Acute Lymphoblastic Leukemia: A Possible Association between Survival Rate and ITPA Polymorphism
title_sort pharmacogenetic analysis of pediatric patients with acute lymphoblastic leukemia: a possible association between survival rate and itpa polymorphism
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3454425/
https://www.ncbi.nlm.nih.gov/pubmed/23029095
http://dx.doi.org/10.1371/journal.pone.0045558
work_keys_str_mv AT kimhyery pharmacogeneticanalysisofpediatricpatientswithacutelymphoblasticleukemiaapossibleassociationbetweensurvivalrateanditpapolymorphism
AT kanghyoungjin pharmacogeneticanalysisofpediatricpatientswithacutelymphoblasticleukemiaapossibleassociationbetweensurvivalrateanditpapolymorphism
AT kimhyojeong pharmacogeneticanalysisofpediatricpatientswithacutelymphoblasticleukemiaapossibleassociationbetweensurvivalrateanditpapolymorphism
AT jangmikyung pharmacogeneticanalysisofpediatricpatientswithacutelymphoblasticleukemiaapossibleassociationbetweensurvivalrateanditpapolymorphism
AT kimnamhee pharmacogeneticanalysisofpediatricpatientswithacutelymphoblasticleukemiaapossibleassociationbetweensurvivalrateanditpapolymorphism
AT ohyongtaek pharmacogeneticanalysisofpediatricpatientswithacutelymphoblasticleukemiaapossibleassociationbetweensurvivalrateanditpapolymorphism
AT hanbyoungdon pharmacogeneticanalysisofpediatricpatientswithacutelymphoblasticleukemiaapossibleassociationbetweensurvivalrateanditpapolymorphism
AT choijiyeob pharmacogeneticanalysisofpediatricpatientswithacutelymphoblasticleukemiaapossibleassociationbetweensurvivalrateanditpapolymorphism
AT kimchulwoo pharmacogeneticanalysisofpediatricpatientswithacutelymphoblasticleukemiaapossibleassociationbetweensurvivalrateanditpapolymorphism
AT leejiwon pharmacogeneticanalysisofpediatricpatientswithacutelymphoblasticleukemiaapossibleassociationbetweensurvivalrateanditpapolymorphism
AT parkkyungduk pharmacogeneticanalysisofpediatricpatientswithacutelymphoblasticleukemiaapossibleassociationbetweensurvivalrateanditpapolymorphism
AT shinheeyoung pharmacogeneticanalysisofpediatricpatientswithacutelymphoblasticleukemiaapossibleassociationbetweensurvivalrateanditpapolymorphism
AT ahnhyoseop pharmacogeneticanalysisofpediatricpatientswithacutelymphoblasticleukemiaapossibleassociationbetweensurvivalrateanditpapolymorphism